These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36892415)

  • 41. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
    Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
    BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Co-twin design in brain imaging-review on biomarkers of Alzheimer's disease.
    Varjonen A; Schwarz C; Vuoksimaa E
    Cereb Cortex; 2023 Jul; 33(14):9054-9066. PubMed ID: 37231165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
    Grothe MJ; Sepulcre J; Gonzalez-Escamilla G; Jelistratova I; Schöll M; Hansson O; Teipel SJ;
    Brain; 2018 Sep; 141(9):2755-2771. PubMed ID: 30016411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regional cerebral tau predicts decline in everyday functioning across the Alzheimer's disease spectrum.
    Dubbelman MA; Mimmack KJ; Sprague EH; Amariglio RE; Vannini P; Marshall GA;
    Alzheimers Res Ther; 2023 Jul; 15(1):120. PubMed ID: 37408004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
    Park JC; Han SH; Yi D; Byun MS; Lee JH; Jang S; Ko K; Jeon SY; Lee YS; Kim YK; Lee DY; Mook-Jung I
    Brain; 2019 Mar; 142(3):771-786. PubMed ID: 30668647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J; Wilson H; Politis M;
    J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study.
    Parbo P; Ismail R; Sommerauer M; Stokholm MG; Hansen AK; Hansen KV; Amidi A; Schaldemose JL; Gottrup H; Brændgaard H; Eskildsen SF; Borghammer P; Hinz R; Aanerud J; Brooks DJ
    Neurobiol Dis; 2018 Sep; 117():211-216. PubMed ID: 29902557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Episodic memory and cortical amyloid pathology: PET study in cognitively discordant twin pairs.
    Lindgren N; Kaprio J; Karjalainen T; Ekblad L; Helin S; Karrasch M; Teuho J; Rinne JO; Vuoksimaa E
    Neurobiol Aging; 2021 Dec; 108():122-132. PubMed ID: 34607247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
    Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC;
    JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
    Ossenkoppele R; Pichet Binette A; Groot C; Smith R; Strandberg O; Palmqvist S; Stomrud E; Tideman P; Ohlsson T; Jögi J; Johnson K; Sperling R; Dore V; Masters CL; Rowe C; Visser D; van Berckel BNM; van der Flier WM; Baker S; Jagust WJ; Wiste HJ; Petersen RC; Jack CR; Hansson O
    Nat Med; 2022 Nov; 28(11):2381-2387. PubMed ID: 36357681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.
    Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y
    Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
    Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [
    Pascoal TA; Chamoun M; Lax E; Wey HY; Shin M; Ng KP; Kang MS; Mathotaarachchi S; Benedet AL; Therriault J; Lussier FZ; Schroeder FA; DuBois JM; Hightower BG; Gilbert TM; Zürcher NR; Wang C; Hopewell R; Chakravarty M; Savard M; Thomas E; Mohaddes S; Farzin S; Salaciak A; Tullo S; Cuello AC; Soucy JP; Massarweh G; Hwang H; Kobayashi E; Hyman BT; Dickerson BC; Guiot MC; Szyf M; Gauthier S; Hooker JM; Rosa-Neto P
    Nat Commun; 2022 Jul; 13(1):4171. PubMed ID: 35853847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease.
    Spotorno N; Strandberg O; Vis G; Stomrud E; Nilsson M; Hansson O
    Brain; 2023 Apr; 146(4):1602-1614. PubMed ID: 36130332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
    Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
    JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease.
    Pereira JB; Janelidze S; Ossenkoppele R; Kvartsberg H; Brinkmalm A; Mattsson-Carlgren N; Stomrud E; Smith R; Zetterberg H; Blennow K; Hansson O
    Brain; 2021 Feb; 144(1):310-324. PubMed ID: 33279949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females.
    Edwards L; La Joie R; Iaccarino L; Strom A; Baker SL; Casaletto KB; Cobigo Y; Grant H; Kim M; Kramer JH; Mellinger TJ; Pham J; Possin KL; Rosen HJ; Soleimani-Meigooni DN; Wolf A; Miller BL; Rabinovici GD
    Neurobiol Aging; 2021 Sep; 105():86-98. PubMed ID: 34049062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.
    Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
    Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.